Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Resmed’s high margin and recurrent-revenue segment are the core...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.84 |
Change
0.410(1.26%) |
Mkt cap ! $20.85B | |||
| Open | High | Low | Value | Volume |
| $32.65 | $32.90 | $32.61 | $21.96M | 670.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 1905 | $32.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.84 | 2346 | 15 |
View Market Depth
| Last trade - 13.32pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.80 |
Change
0.410 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| $32.62 | $32.89 | $32.62 | 83206 | ||
| Last updated 13.52pm 21/05/2024 ? | |||||
| RMD (ASX) Chart |